T2 Biosystems, Inc. Stock

TTOO

US89853L3024

Advanced Medical Equipment & Technology

Market Closed - OTC Markets 12:03:41 2026-05-29 EDT			5-day change	1st Jan Change
0.000400 ^USD	-.--%		-20.00%	-92.00%

02-03	T2 Biosystems announces intent to wind down operations	RE
02-03	T2 Biosystems, Inc. Announces Intent to Complete Winding Down of Operations	CI

Valuation: T2 Biosystems, Inc.

Market Cap	28.04K 24.22K 22.76K 20.7K 38.92K 2.68M 39.56K 267K 104K 1.34M 105K 103K 4.46M	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	28.04K 24.22K 22.76K 20.7K 38.92K 2.68M 39.56K 267K 104K 1.34M 105K 103K 4.46M	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	94.62%	Yield 2026 *	-	Yield 2027 *	-

* Estimated data More valuation ratios

Latest news : T2 Biosystems, Inc.

02-03	T2 Biosystems announces intent to wind down operations	RE
02-03	T2 Biosystems, Inc. Announces Intent to Complete Winding Down of Operations	CI
25-04-07	T2 Biosystems, Inc. Announces CFO Changes	CI
25-04-07	T2 Biosystems, Inc. Announces Board and Committee Changes	CI
25-02-20	T2 Biosystems, Inc. Approves Reduction-In-Force of Substantially All of Its Employees	CI
25-02-13	T2 Biosystems, Inc.(OTCPK:TTOO) dropped from S&P TMI Index	CI
25-02-11	T2 Biosystems Gets Nasdaq Delisting Notice; Shares Down	MT
25-02-10	T2 Biosystems, Inc.(OTCPK:TTOO) dropped from NASDAQ Composite Index	CI
24-12-18	T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor	CI
24-12-17	T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally	CI
24-12-16	T2 Biosystems Extends Capital Equipment Supplier Deal With Vizient; Shares Rise	MT
24-12-16	T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc	CI
24-12-09	T2 Biosystems, Inc. Announces Plans to License Its Proprietary Technology to Expand Its Leadership in Direct-From-Whole- Blood Detection of Sepsis-Causing Pathogens	CI

More news

Analysts' recommendations: T2 Biosystems, Inc.

24-04-29	Canaccord Genuity Adjusts Price Target on T2 Biosystems to $3 From $12, Maintains Hold Rating	MT
23-07-13	Alliance Global Partners Adjusts Price Target on T2 Biosystems to 7 cents From 12 cents, Maintains Neutral Rating	MT
23-01-24	Alliance Global Adjusts Price Target on T2 Biosystems to $1.50 From $2.20, Maintains Neutral Rating	MT
22-10-14	Canaccord Genuity Downgrades T2 Biosystems to Hold From Buy, Adjusts Price Target to $2.50 From $12.50	MT
22-07-07	Alliance Global Downgrades T2 Biosystems to Neutral from Buy, Lowers Price Target to $0.14 From $0.65	MT

More recommendations

Press Releases: T2 Biosystems, Inc.

25-01-07	T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results	AQ
24-12-18	T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor	AQ
24-12-17	T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally	AQ
24-12-16	T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.	AQ
24-12-09	T2 Biosystems : Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct From Whole Blood Detection of Sepsis Causing Pathogens Form 8 K	PU

More press releases

News in other languages: T2 Biosystems, Inc.

24-05-07	MÄRKTE USA/Rally geht langsam die Puste aus - Disney unter Druck
24-05-07	MÄRKTE USA/Rally dürfte auslaufen
23-07-06	Meta lance Threads, une application pour concurrencer Twitter
23-07-05	Meta lance Threads, une application pour concurrencer Twitter

More news

Managers and Directors: T2 Biosystems, Inc.

Manager	Title	Age	Since
Craig Jalbert CEO	Chief Executive Officer	64	2025-04-02
Roger Smith CTO	Chief Tech/Sci/R&D Officer	61	-
Brett Giffin PRN	Corporate Officer/Principal	68	2021-11-07

Director	Title	Age	Since
Ninfa Saunders BRD	Director/Board Member	74	2020-06-13
Craig Jalbert BRD	Director/Board Member	64	2025-04-02

More insiders

Other Advanced Medical Equipment & Technology

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
T2 BIOSYSTEMS, INC.	-.--%	-20.00%	-98.18%	-100.00%	28.04K
THERMO FISHER SCIENTIFIC, INC.	-1.28%	-0.96%	+20.30%	+10.08%	218B
DANAHER CORPORATION	-0.71%	-1.13%	-4.02%	-20.68%	142B
INTUITIVE SURGICAL, INC.	-1.68%	+4.14%	-17.85%	+28.66%	139B
BOSTON SCIENTIFIC CORPORATION	+0.27%	+5.11%	-49.76%	+0.29%	75.11B
EDWARDS LIFESCIENCES CORPORATION	-1.04%	+2.10%	+17.05%	+14.70%	52.8B
SIEMENS HEALTHINEERS AG	+0.69%	-0.51%	-16.49%	-15.50%	50.66B
AGILENT TECHNOLOGIES, INC.	-0.51%	+1.75%	+24.61%	+18.21%	41.95B
WATERS CORPORATION	-0.32%	+1.31%	+41.37%	+44.38%	40.49B
GE HEALTHCARE TECHNOLOGIES INC.	-0.14%	+2.68%	+0.40%	+4.47%	33.28B
Average	-0.47%	+1.60%	-8.26%	-1.54%	79.35B
Weighted average by Cap.	-0.82%	+1.23%	+0.51%	+7.52%

See all sector performances

T2 Biosystems, Inc. is an in vitro diagnostics company focused on the detection of sepsis-causing pathogens and antibiotic resistance genes. Its technology enables detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its focus includes three areas: sepsis, bioterrorism, and Lyme disease. The Company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the T2 Magnetic Resonance (T2MR) technology. It also has an active pipeline of products, including the United States T2Resistance Panel, the Candida auris test, and the T2Lyme Panel. T2Dx Instrument is a fully automated instrument that is capable of running a range of diagnostic tests from patient samples.

Employees

113

Sector

Advanced Medical Equipment & Technology

More about the company